Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Roche Holding AG (RO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
369.60 -5.00    -1.33%
18/06 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012032113 
VALOR:  1203211
  • Volume: 150,171
  • Bid/Ask: 369.60 / 371.20
  • Day's Range: 369.60 - 374.60
Roche Holding 369.60 -5.00 -1.33%

RO Historical Data

 
Get free historical data for RO. You'll find the closing price, open, high, low, change and %change of the Roche Holding AG Stock for the selected range of dates. The data can be viewed in daily, weekly or monthly time intervals. At the bottom of the table you'll find the data summary for the selected range of dates.
Time Frame:
05/20/2021 - 06/19/2021
 
Download Data
Date Price Open High Low Vol. Change %
Jun 18, 2021 369.60 372.40 374.60 369.60 150.17K -1.33%
Jun 17, 2021 374.60 369.40 374.60 367.20 61.43K 0.75%
Jun 16, 2021 371.80 367.80 371.80 366.00 45.52K 1.09%
Jun 15, 2021 367.80 366.60 367.80 363.80 43.29K 0.55%
Jun 14, 2021 365.80 365.00 366.60 363.20 33.78K 0.16%
Jun 11, 2021 365.20 362.40 366.00 361.80 50.07K 0.44%
Jun 10, 2021 363.60 361.80 363.60 359.60 50.51K 0.66%
Jun 09, 2021 361.20 348.80 361.20 347.80 54.05K 3.26%
Jun 08, 2021 349.80 347.60 352.00 346.80 63.22K 0.63%
Jun 07, 2021 347.60 340.60 348.00 339.60 63.20K 1.46%
Jun 04, 2021 342.60 338.60 342.60 337.40 33.94K 1.12%
Jun 03, 2021 338.80 332.60 338.80 331.60 42.13K 0.77%
Jun 02, 2021 336.20 336.40 338.40 334.40 59.92K -0.12%
Jun 01, 2021 336.60 337.80 339.60 336.00 50.26K -0.12%
May 31, 2021 337.00 338.00 340.00 336.40 34.78K -0.94%
May 28, 2021 340.20 338.40 341.40 335.60 65.48K 0.24%
May 27, 2021 339.40 339.20 341.20 336.80 564.21K -0.29%
May 26, 2021 340.40 337.80 342.20 337.80 77.48K 0.53%
May 25, 2021 338.60 337.00 339.60 337.00 82.65K 0.59%
May 21, 2021 336.60 335.00 336.60 333.20 88.75K 0.66%
May 20, 2021 334.40 332.00 334.40 330.60 78.93K 1.27%
May 19, 2021 330.20 329.00 332.40 326.80 61.59K 0.00%
Highest: 374.60 Lowest: 326.80 Difference: 47.80 Average: 349.45 Change %: 11.93
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Reply
0 0
Report
Ruta Rublevska
Ruta Rublevska Nov 16, 2020 3:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Reply
1 0
Report
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just like Biolidics. they get approval for Covid19 tests kits in USA
Reply
1 0
Report
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
0 0
Report
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is the historical price adjusted for stock splits?
Reply
2 0
Report
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email